Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-12-01T04:38:20.819Z Has data issue: false hasContentIssue false
  • English
  • Français

Utility of Dual Skin Tests to Evaluate Tuberculin Skin Test Reactions of 10 to 14 mm in Healthcare Workers

Published online by Cambridge University Press:  02 January 2015

Bryan J. Marsh ,
Joshua San Vicente  and
C. Fordham von Reyn
Bryan J. Marsh*
Affiliation:
Infectious Disease Section, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Joshua San Vicente
Affiliation:
Infectious Disease Section, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
C. Fordham von Reyn
Affiliation:
Infectious Disease Section, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
*
Infectious Disease Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To define the utility of 10- to 14-mm reactions to a Mycobacterium tuberculosis purified protein derivative (PPD) skin test for healthcare workers (HCWs).

Design:

Blinded dual skin testing, using PPD and M. avium sensitin, of HCWs at a single medical center who had a 10-to 14-mm reaction to PPD when tested by personnel from the Occupational Health Department as part of routine annual screening.

Setting:

A single tertiary-care academic medical center.

Participants:

Employees of the medical center who underwent routine annual PPD screening and were identified by the Occupational Health Department as having a reaction of 10 to 14 mm to PPD.

Results:

Nineteen employees were identified as candidates and 11 underwent dual skin testing. Only 4 (36%) had repeat results for PPD in the 10- to 14-mm range, whether read by Occupational Health Department personnel or study investigators. For only 5 (45%) of the subjects did the Occupational Health Department personnel and study investigators concur (± 3 mm) on the size of the PPD reaction. Two of the 4 subjects with reactions of 10 to 14 mm as measured by the study investigators were M. avium sensitin dominant, 1 was PPD dominant, and 1 was nondominant.

Conclusion:

A reaction of 10 to 14 mm to PPD should not be used as an indication for the treatment of latent tuberculosis (TB) infection in healthy HCWs born in the United States with no known exposure to TB.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 24 , Issue 11 , November 2003 , pp. 821 - 824
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis. Am J Respir Crit Care Med 2000;161 (suppl) :S221–S247.Google Scholar
2. Daniel, TM. The occupational tuberculosis risk of health care workers. In: Field, MJ, ed. Tuberculosis in the Workplace. Washington, DC: National Academy Press; 2001:189–229.Google Scholar
3. Larsen, NM, Biddle, CL, Sotir, MJ, White, N, Parrott, P, Blumberg, HM. Risk of tuberculin skin test conversion among health care workers: occupational versus community exposure and infection. Clin Infect Dis 2002;35:796–801.Google Scholar
4. von Reyn, CF, Horsburgh, CR, Olivier, KN, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001;5:1122–1128.Google Scholar
5. von Reyn, CF, Williams, DE, Horsburgh, CR, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative to discriminate pulmonary disease due to M. avium complex from pulmonary disease due to Mycobacterium tuberculosis . J Infect Dis 1998;177:730–736.CrossRefGoogle Scholar
6. Pouchot, J, Grasland, A, Collet, C, Coste, J, Esdaile, JM, Vinceneux, P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997;126:210–214.CrossRefGoogle ScholarPubMed
7. Longfield, JN, Margileth, AM, Golden, SM, Lazoritz, S, Bohan, S, Cruess, DF. Interobserver and method variability in tuberculin skin testing. Pediatr Infect Dis J 1984;3:323–326.Google Scholar
8. Kendig, EL Jr, Kirkpatrick, BV, Carter, WH, Hill, FA, Caldwell, K, Entwistle, M. Underreading of the tuberculin skin test reaction. Chest 1998;113:1175–1177.Google Scholar
9. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection: United States, 2003. MMWR 2003;52:735–739.Google Scholar
10. Hersh, A, von Reyn, CF. Interferon assay compared to tuberculin testing for latent tuberculosis. JAMA 2002;287:450–451.Google Scholar